Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Shares Down 6% – Time to Sell?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) shares traded down 6% on Tuesday . The company traded as low as $23.74 and last traded at $23.7340. 249,300 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 675,643 shares. The stock had previously closed at $25.26.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on FMS shares. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, May 6th. Wall Street Zen downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Zacks Research upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective on the stock. in a research note on Tuesday, July 28th. Finally, Truist Financial set a $25.00 target price on Fresenius Medical Care AG & Co. KGaA in a report on Wednesday. Six research analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA presently has an average rating of “Reduce” and a consensus target price of $22.45.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.4%

The stock has a market cap of $12.84 billion, a PE ratio of 12.39, a price-to-earnings-growth ratio of 4.27 and a beta of 0.77. The company’s 50-day moving average price is $23.49 and its 200 day moving average price is $22.99. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.86 and a current ratio of 1.07.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.04. The company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. On average, sell-side analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.22 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Institutional investors have recently added to or reduced their stakes in the stock. Pzena Investment Management LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 2.0% in the 1st quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after buying an additional 299,986 shares during the period. Morgan Stanley grew its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% in the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after purchasing an additional 942,497 shares in the last quarter. Integral Health Asset Management LLC lifted its holdings in Fresenius Medical Care AG & Co. KGaA by 44.4% during the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after buying an additional 200,000 shares in the last quarter. Moran Wealth Management LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the first quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after acquiring an additional 83,311 shares in the last quarter. Finally, Quantinno Capital Management LP raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 15.7% in the first quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock valued at $7,701,000 after acquiring an additional 46,428 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.